Sunder Mudaliar
Overview
Explore the profile of Sunder Mudaliar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
3283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ekanayake P, Hupfeld C, Mudaliar S
Curr Diab Rep
. 2020 Nov;
20(12):74.
PMID: 33230620
Purpose Of Review: The micro/macrovascular complications of diabetes cause considerable morbidity and premature mortality. The SGLT2 inhibitors are the first diabetes medications with significant benefits on microvascular disease (nephropathy) and...
12.
Edelman S, Olefsky J, Mudaliar S, Ciaraldi T, Baron A
Diabetes Care
. 2020 Jan;
43(3):522-525.
PMID: 31964787
No abstract available.
13.
Mudaliar S
Cardiovasc Endocrinol Metab
. 2019 Oct;
7(1):24-27.
PMID: 31646275
Patients with type 2 diabetes suffer from both microvascular and macrovascular complications. Optimal glycemic control is well known to reduce the microvascular complications of retinopathy, nephropathy, and neuropathy. However, despite...
14.
Nathan D, Bennett P, Crandall J, Edelstein S, Goldberg R, Kahn S, et al.
Diabetologia
. 2019 Jul;
62(8):1319-1328.
PMID: 31270584
The global epidemic of type 2 diabetes has prompted numerous studies and public health efforts to reduce its development. A variety of interventions, including lifestyle modifications and pharmacological agents directed...
15.
Hupfeld C, Mudaliar S
Diabetes Obes Metab
. 2019 Apr;
21(8):1780-1789.
PMID: 30957945
The publication of results from recent cardiovascular outcome trials (CVOTs) has transformed the landscape of diabetes treatment. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose co-transporter-2 (SGLT2) inhibitors have demonstrated...
16.
Shekhawat V, Bhansali S, Dutta P, Mukherjee K, Vaiphei K, Kochhar R, et al.
Sci Rep
. 2019 Apr;
9(1):5646.
PMID: 30948746
Impaired insulin sensitivity (IS) and β-cell dysfunction result in hyperglycaemia in patients of acromegaly. However, alterations in incretins and their impact on glucose-insulin homeostasis in these patients still remain elusive....
17.
Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, et al.
Diabetes Obes Metab
. 2018 Nov;
21(4):812-821.
PMID: 30447037
Aim: To evaluate the impact of the sodium glucose co-transporter 2 inhibitor canagliflozin on intrahepatic triglyceride (IHTG) accumulation and its relationship to changes in body weight and glucose metabolism. Materials...
18.
Bhansali S, Dutta P, Yadav M, Jain A, Mudaliar S, Hawkins M, et al.
Diabetol Metab Syndr
. 2017 Jul;
9:50.
PMID: 28690682
Background: Insulin resistance and insulin deficiency are the cardinal defects in the pathogenesis of type 2 diabetes mellitus (T2DM). Despite the plethora of anti-diabetic medications, drugs specifically targeting the β-cells...
19.
Henry R, Dandona P, Pettus J, Mudaliar S, Xu J, Hansen L
Diabetes Obes Metab
. 2017 Jan;
19(6):814-821.
PMID: 28098426
Aims: To investigate the effects of total daily insulin dose (TDD) reductions on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate (a marker for diabetic ketosis/ketoacidosis [DKA]) levels, using patient-level...
20.
Bhansali S, Dutta P, Kumar V, Yadav M, Jain A, Mudaliar S, et al.
Stem Cells Dev
. 2016 Dec;
26(7):471-481.
PMID: 28006991
Drugs targeting β-cells have provided new options in the management of T2DM; however, their role in β-cell regeneration remains elusive. The recent emergence of cell-based therapies such as autologous bone...